Gastardelo Thaís Santana, Cunha Bianca Rodrigues, Raposo Luís Sérgio, Maniglia José Victor, Cury Patrícia Maluf, Lisoni Flávia Cristina Rodrigues, Tajara Eloiza Helena, Oliani Sonia Maria
From the Post-graduation in Structural and Functional Biology, Federal University of São Paulo (UNIFESP), Paulista School of Medicine (EPM), São Paulo, SP, Brazil.
Department of Molecular Biology, Faculty of Medicine (FAMERP), São José do Rio Preto, SP, Brazil.
PLoS One. 2014 Dec 9;9(12):e111317. doi: 10.1371/journal.pone.0111317. eCollection 2014.
The anti-inflammatory protein annexin A1 (ANXA1) has been associated with cancer progression and metastasis, suggesting its role in regulating tumor cell proliferation. We investigated the mechanism of ANXA1 interaction with formylated peptide receptor 2 (FPR2/ALX) in control, peritumoral and tumor larynx tissue samples from 20 patients, to quantitate the neutrophils and mast cells, and to evaluate the protein expression and co-localization of ANXA1/FPR2 in these inflammatory cells and laryngeal squamous cells by immunocytochemistry. In addition, we performed in vitro experiments to further investigate the functional role of ANXA1/FPR2 in the proliferation and metastasis of Hep-2 cells, a cell line from larynx epidermoid carcinoma, after treatment with ANXA1(2-26) (annexin A1 N-terminal-derived peptide), Boc2 (antagonist of FPR) and/or dexamethasone. Under these treatments, the level of Hep-2 cell proliferation, pro-inflammatory cytokines, ANXA1/FPR2 co-localization, and the prostaglandin signalling were analyzed using ELISA, immunocytochemistry and real-time PCR. An influx of neutrophils and degranulated mast cells was detected in tumor samples. In these inflammatory cells of peritumoral and tumor samples, ANXA1/FPR2 expression was markedly exacerbated, however, in laryngeal carcinoma cells, this expression was down-regulated. ANXA1(2-26) treatment reduced the proliferation of the Hep-2 cells, an effect that was blocked by Boc2, and up-regulated ANXA1/FPR2 expression. ANXA1(2-26) treatment also reduced the levels of pro-inflammatory cytokines and affected the expression of metalloproteinases and EP receptors, which are involved in the prostaglandin signalling. Overall, this study identified potential roles for the molecular mechanism of the ANXA1/FPR2 interaction in laryngeal cancer, including its relationship with the prostaglandin pathway, providing promising starting points for future research. ANXA1 may contribute to the regulation of tumor growth and metastasis through paracrine mechanisms that are mediated by FPR2/ALX. These data may lead to new biological targets for therapeutic intervention in human laryngeal cancer.
抗炎蛋白膜联蛋白A1(ANXA1)与癌症进展和转移相关,提示其在调节肿瘤细胞增殖中发挥作用。我们研究了20例患者对照、瘤旁和肿瘤喉组织样本中ANXA1与甲酰化肽受体2(FPR2/ALX)相互作用的机制,定量中性粒细胞和肥大细胞,并通过免疫细胞化学评估这些炎症细胞和喉鳞状细胞中ANXA1/FPR2的蛋白表达及共定位。此外,我们进行了体外实验,以进一步研究ANXA1(2-26)(膜联蛋白A1 N端衍生肽)、Boc2(FPR拮抗剂)和/或地塞米松处理后,ANXA1/FPR2在喉表皮样癌细胞系Hep-2细胞增殖和转移中的功能作用。在这些处理下,使用酶联免疫吸附测定、免疫细胞化学和实时聚合酶链反应分析Hep-2细胞增殖水平、促炎细胞因子、ANXA1/FPR2共定位及前列腺素信号传导。在肿瘤样本中检测到中性粒细胞流入和肥大细胞脱颗粒。在瘤旁和肿瘤样本的这些炎症细胞中,ANXA1/FPR2表达明显加剧,然而,在喉癌细胞中,这种表达下调。ANXA1(2-26)处理降低了Hep-2细胞的增殖,这一效应被Boc2阻断,并上调了ANXA1/FPR2表达。ANXA1(2-26)处理还降低了促炎细胞因子水平,并影响了参与前列腺素信号传导的金属蛋白酶和EP受体的表达。总体而言,本研究确定了ANXA1/FPR2相互作用分子机制在喉癌中的潜在作用,包括其与前列腺素途径的关系,为未来研究提供了有前景的起点。ANXA1可能通过FPR2/ALX介导的旁分泌机制有助于调节肿瘤生长和转移。这些数据可能为人类喉癌治疗干预带来新的生物学靶点。